{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T12:31:35Z","timestamp":1787920295265,"version":"build-2784847793"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T00:00:00Z","timestamp":1594684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T00:00:00Z","timestamp":1594684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"National Science and Technology Key Projects","award":["2017ZX09304029004"],"award-info":[{"award-number":["2017ZX09304029004"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s12185-020-02936-4","type":"journal-article","created":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T15:03:51Z","timestamp":1594739031000},"page":"568-576","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Short-term effectiveness of ruxolitinib in the treatment of recurrent or refractory hemophagocytic lymphohistiocytosis in children"],"prefix":"10.1007","volume":"112","author":[{"given":"Ang","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honghao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyun","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,14]]},"reference":[{"issue":"13","key":"2936_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1146\/annurev-pathol-020117-043625","volume":"24","author":"H Al-Samkari","year":"2018","unstructured":"Al-Samkari H, Berliner N. Hemophagocytic Lymphohistiocytosis. Annu Rev Pathol. 2018;24(13):27\u201349.","journal-title":"Annu Rev Pathol"},{"issue":"9","key":"2936_CR2","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1111\/ped.13064","volume":"58","author":"A Morimoto","year":"2016","unstructured":"Morimoto A, Nakazawa Y, Ishii E. Hemophagocytic lymphohistiocytosis: pathogenesis, diagnosis, and management. Pediatr Int. 2016;58(9):817\u201325.","journal-title":"Pediatr Int"},{"issue":"25","key":"2936_CR3","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1182\/blood-2017-06-788349","volume":"130","author":"E Bergsten","year":"2017","unstructured":"Bergsten E, Horne A, Aric\u00f3 M, Astigarraga I, Egeler RM, Filipovich AH, Ishii E, Janka G, et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood. 2017;130(25):2728\u201338.","journal-title":"Blood"},{"issue":"4","key":"2936_CR4","doi-asserted-by":"publisher","first-page":"214","DOI":"10.4110\/in.2017.17.4.214","volume":"17","author":"M Lee","year":"2017","unstructured":"Lee M, Rhee I. Cytokine signaling in tumor progression. Immune Netw. 2017;17(4):214\u201327.","journal-title":"Immune Netw"},{"issue":"9","key":"2936_CR5","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrc2210","volume":"7","author":"RL Levine","year":"2007","unstructured":"Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer. 2007;7(9):673\u201383.","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"2936_CR6","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1182\/blood-2018-07-858720","volume":"132","author":"L Arcaini","year":"2018","unstructured":"Arcaini L, Cazzola M. Benefits and risks of JAK inhibition. Blood. 2018;132(7):675\u20136.","journal-title":"Blood"},{"issue":"22","key":"2936_CR7","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1182\/blood-2018-01-791491","volume":"131","author":"F Passamonti","year":"2018","unstructured":"Passamonti F, Maffioli M. The role of JAK2 inhibitors in MPNs 7 years after approval. Blood. 2018;131(22):2426\u201335.","journal-title":"Blood"},{"key":"2936_CR8","doi-asserted-by":"publisher","first-page":"e622","DOI":"10.1542\/peds.2006-3164","volume":"120","author":"N Mahlaoui","year":"2007","unstructured":"Mahlaoui N, Ouach\u00e9e-Chardin M, de Saint BG, Neven B, Picard C, Blanche S. Fischer A Immunotherapy of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins: single-center retrospective report of 38 patients. Pediatrics. 2007;120:e622\u2013e628628.","journal-title":"Pediatrics"},{"key":"2936_CR9","doi-asserted-by":"publisher","first-page":"194864","DOI":"10.1155\/2015\/194864","volume":"2015","author":"G Lopalco","year":"2015","unstructured":"Lopalco G, Cantarini L, Vitale A, Iannone F, Anelli MG, Andreozzi L, Lapadula G, et al. Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives. Mediators Inflamm. 2015;2015:194864.","journal-title":"Mediators Inflamm"},{"key":"2936_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12969-015-0006-z","volume":"13","author":"C De Pieri","year":"2015","unstructured":"De Pieri C, Vuch J, De Martino E, Bianco AM, Ronfani L, Athanasakis E, Bortot B, et al. Genetic profiling of autoinflammatory disorders in patients with periodic fever: a prospective study. Pediatric Rheumatol Online J. 2015;13:11.","journal-title":"Pediatric Rheumatol Online J"},{"issue":"19","key":"2936_CR11","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1182\/blood-2015-05-644914","volume":"126","author":"Y Wang","year":"2015","unstructured":"Wang Y, Huang W, Hu L, Cen X, Li L, Wang J, Shen J, et al. Multicenter study of combination DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis. Blood. 2015;126(19):2186\u201392.","journal-title":"Blood"},{"issue":"24","key":"2936_CR12","doi-asserted-by":"publisher","first-page":"3832","DOI":"10.1182\/blood-2013-12-543736","volume":"123","author":"S Spoerl","year":"2014","unstructured":"Spoerl S, Mathew NR, Bscheider M, Schmitt-Graeff A, Chen S, Mueller T, Verbeek M, et al. Activity of therapeutic JAK 1\/2 blockade in graft-versus-host disease. Blood. 2014;123(24):3832\u201342.","journal-title":"Blood"},{"issue":"10","key":"2936_CR13","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1080\/10245332.2018.1491093","volume":"23","author":"W Lai","year":"2018","unstructured":"Lai W, Wang Y, Wang J, Wu L, Jin Z, Wang Z. Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults and adolescents-a life-threatening disease: analysis of 133 cases from a single center. Hematology. 2018;23(10):810\u20136.","journal-title":"Hematology"},{"issue":"2","key":"2936_CR14","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s12185-018-02572-z","volume":"109","author":"R Yanagisawa","year":"2019","unstructured":"Yanagisawa R, Nakazawa Y, Matsuda K, Yasumi T, Kanegane H, Ohga S, Morimoto A, et al. Outcomes in children with hemophagocytic lymphohistiocytosis treated using HLH-2004 protocol in Japan. Int J Hematol. 2019;109(2):206\u201313.","journal-title":"Int J Hematol"},{"issue":"7","key":"2936_CR15","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1182\/blood-2002-01-0172","volume":"100","author":"JI Henter","year":"2002","unstructured":"Henter JI, Samuelsson-Horne A, Aric\u00f3 M, Egeler RM, Elinder G, Filipovich AH, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002;100(7):2367\u201373.","journal-title":"Blood"},{"issue":"11","key":"2936_CR16","doi-asserted-by":"publisher","first-page":"e27929","DOI":"10.1002\/pbc.27929","volume":"66","author":"MB Jordan","year":"2019","unstructured":"Jordan MB, Allen CE, Greenberg J, Henry M, Hermiston ML, Kumar A, Hines M, et al. Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO). Pediatr Blood Cancer. 2019;66(11):e27929.","journal-title":"Pediatr Blood Cancer"},{"issue":"23","key":"2936_CR17","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1182\/blood.2018894618","volume":"133","author":"P La Ros\u00e9e","year":"2019","unstructured":"La Ros\u00e9e P, Horne A, Hines M, von Bahr GT, Machowicz R, Berliner N, Birndt S, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019;133(23):2465\u201377.","journal-title":"Blood"},{"issue":"4","key":"2936_CR18","doi-asserted-by":"publisher","first-page":"e26308","DOI":"10.1002\/pbc.26308","volume":"64","author":"RA Marsh","year":"2017","unstructured":"Marsh RA, Jordan MB, Talano JA, Nichols KE, Kumar A, Naqvi A, Vaiselbuh SR. Histiocyte Society Salvage Therapy Working Group. Salvage therapy for refractory hemophagocytic lymphohistiocytosis: a review of the published experience. Pediatr Blood Cancer. 2017;64(4):e26308.","journal-title":"Pediatr Blood Cancer."},{"issue":"2","key":"2936_CR19","doi-asserted-by":"publisher","first-page":"E47","DOI":"10.1002\/ajh.24971","volume":"93","author":"J Slostad","year":"2017","unstructured":"Slostad J, Hoversten P, Haddox CL, Cisak K, Paludo J, Tefferi A. Ruxolitinib as first- line treatment in secondary hemophagocytic lymphohistiocytosis: a single patient experience. Am J Hematol. 2017;93(2):E47\u2013E4949.","journal-title":"Am J Hematol"},{"issue":"5","key":"2936_CR20","doi-asserted-by":"publisher","first-page":"E123","DOI":"10.1002\/ajh.25063","volume":"93","author":"I Zandvakili","year":"2018","unstructured":"Zandvakili I, Conboy CB, Ayed AO, Cathcart-Rake EJ, Tefferi A. Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: a second experience. Am J Hematol. 2018;93(5):E123\u2013E125125.","journal-title":"Am J Hematol"},{"issue":"16","key":"2936_CR21","first-page":"S1658","volume":"8","author":"JH Sin","year":"2017","unstructured":"Sin JH, Zangardi ML. Ruxolitinib for secondary hemophagocytic lymphohistiocytosis: first case report. Hematol Oncol Stem Cell Ther. 2017;8(16):S1658\u2013S16661666.","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"19","key":"2936_CR22","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1182\/bloodadvances.2017007526","volume":"1","author":"L Broglie","year":"2017","unstructured":"Broglie L, Pommert L, Rao S, Thakar M, Phelan R, Margolis D, Talano J. Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis. Blood Adv. 2017;1(19):1533\u20136.","journal-title":"Blood Adv"},{"issue":"02","key":"2936_CR23","first-page":"219","volume":"31","author":"L Chen","year":"2018","unstructured":"Chen L, You Y, Zhang WJ, Shao J, Guo LY, Wang HX, Zhong ZD. Efficacy of ruxolitinib in adult hemophagocytics syndrome. Clin Hematol (China). 2018;31(02):219\u201321.","journal-title":"Clin Hematol (China)"},{"issue":"3","key":"2936_CR24","first-page":"315","volume":"54","author":"MN Zhai","year":"2019","unstructured":"Zhai MN, Shi XD. Clinical analysis of ruxolitinib in the treatment of hemophagocytic lymphohistiocytosis in children. Chin J Medi. 2019;54(3):315\u20137.","journal-title":"Chin J Medi"},{"issue":"1","key":"2936_CR25","first-page":"73","volume":"40","author":"JS Wang","year":"2019","unstructured":"Wang JS, Wang YN, Wu L, Lai WY, Wang Z. Refractory\/relapsed hemophagocytic lymphohistiocytosis treated with ruxolitinib: three cases report and literatures review. Chin J Hematol. 2019;40(1):73\u20135.","journal-title":"Chin J Hematol"},{"issue":"23","key":"2936_CR26","doi-asserted-by":"publisher","first-page":"4131","DOI":"10.1182\/bloodadvances.2019000898","volume":"3","author":"SR Goldsmith","year":"2019","unstructured":"Goldsmith SR, Saif Ur Rehman S, Shirai CL, Vij K, DiPersio JF. Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1\/2 inhibitor ruxolitinib. Blood Adv. 2019;3(23):4131\u20135.","journal-title":"Blood Adv"},{"issue":"3","key":"2936_CR27","doi-asserted-by":"crossref","first-page":"e28071","DOI":"10.1002\/pbc.28071","volume":"67","author":"KM Ramanan","year":"2019","unstructured":"Ramanan KM, Uppuluri R, Ravichandran N, Patel S, Swaminathan VV, Jayakumar I, Raj R. Successful remission induction in refractory familial hemophagocytic lymphohistiocytosis with ruxolitinib as a bridge to hematopoietic stem cell transplantation. Pediatr Blood Cancer. 2019;67(3):e28071.","journal-title":"Pediatr Blood Cancer."},{"issue":"2","key":"2936_CR28","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1182\/blood.2019000761","volume":"134","author":"S Albeituni","year":"2019","unstructured":"Albeituni S, Verbist KC, Tedrick PE, Tillman H, Picarsic J, Bassett R, Nichols KE. Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis. J Blood. 2019;134(2):147\u201359.","journal-title":"J Blood"},{"issue":"15","key":"2936_CR29","first-page":"1137","volume":"27","author":"YM Tang","year":"2012","unstructured":"Tang YM, Chen YY. Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis and its molecule biological pathogenesis. Appl Clin Pediatr. 2012;27(15):1137\u201340.","journal-title":"Appl Clin Pediatr"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-02936-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-020-02936-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-02936-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T06:55:34Z","timestamp":1696402534000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-020-02936-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,14]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["2936"],"URL":"https:\/\/doi.org\/10.1007\/s12185-020-02936-4","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,14]]},"assertion":[{"value":"25 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"No financial.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board (IRB) of Beijing Children\u2019s Hospital, Capital Medical University. All parents signed informed consent forms.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}